Abiomed, Inc. (ABMD)
| Market Cap | 13.23B |
| Revenue (ttm) | 1.06B |
| Net Income (ttm) | 217.58M |
| Shares Out | 45.46M |
| EPS (ttm) | 4.96 |
| PE Ratio | 58.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,955 |
| Open | 295.85 |
| Previous Close | 293.34 |
| Day's Range | 289.54 - 301.49 |
| 52-Week Range | 219.85 - 379.30 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 332.35 (+14.2%) |
| Earnings Date | Aug 4, 2022 |
About ABMD
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous ... [Read more...]
Financial Performance
In 2021, Abiomed's revenue was $1.03 billion, an increase of 21.74% compared to the previous year's $847.52 million. Earnings were $136.51 million, a decrease of -39.47%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for ABMD stock is "Buy." The 12-month stock price forecast is 332.35, which is an increase of 14.24% from the latest price.
News
Why Shares of Abiomed Rose 18.4% in July
The company's stock rose steadily throughout the month.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Abiomed (ABMD) Q1 Earnings Top Estimates
Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces first quarter record revenue of $277 million, up 10% year over year, up 12% in constant currency.
Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Medical Device Stocks With Extremely High GF Scores
The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperf...
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on heart failure opportunity with Impella 5.5 and Impella BTR heart pumps.
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will feature the most recent Impella research, technological advances aimed at improving AMICS patient outcomes at SCAI Scientific Sessions.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces fourth quarter record revenue of $270 million, up 12% year over year.
World's First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR).
NACD New England Honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, and Jack F.
BOSTON--(BUSINESS WIRE)---- $ABMD #NACD--Corporate governance award: NACD New England honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, Jack F. O'Brien on May 4
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.
First Patient in Japan Treated with Impella 5.5 with SmartAssist
DANVERS, Mass.--(BUSINESS WIRE)--The first patient in Japan has been treated with Abiomed's Impella 5.5 with SmartAssist and the number of patients treated globally surpasses 5,000.
Abiomed CEO discusses company growth and combining products with supportive technology
The "Mad Money" host spoke with Abiomed CEO Mike Minogue on Monday's episode of the show.
Abiomed to Host Investor Call on Impella ECP, the World's Smallest Heart Pump at 9 French
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on Impella ECP, the world's smallest heart pump at 9 french.